Michael Andrew Chambers Buys 57,100 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPTGet Rating) Director Michael Andrew Chambers bought 57,100 shares of the stock in a transaction dated Wednesday, September 14th. The stock was bought at an average price of $104.43 per share, with a total value of $5,962,953.00. Following the purchase, the director now owns 108,178 shares of the company’s stock, valued at approximately $11,297,028.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Michael Andrew Chambers also recently made the following trade(s):

  • On Friday, August 19th, Michael Andrew Chambers bought 46,170 shares of Sarepta Therapeutics stock. The stock was bought at an average price of $108.28 per share, with a total value of $4,999,287.60.

Sarepta Therapeutics Trading Up 1.2 %

Shares of NASDAQ SRPT opened at $111.99 on Friday. The company has a market cap of $9.81 billion, a price-to-earnings ratio of -19.08 and a beta of 1.20. Sarepta Therapeutics, Inc. has a 12-month low of $61.28 and a 12-month high of $120.23. The company has a current ratio of 4.53, a quick ratio of 4.14 and a debt-to-equity ratio of 1.52. The stock’s 50 day simple moving average is $101.39 and its 200 day simple moving average is $84.35.

Analyst Ratings Changes

SRPT has been the subject of a number of recent research reports. Royal Bank of Canada increased their target price on Sarepta Therapeutics from $160.00 to $182.00 and gave the company an “outperform” rating in a research note on Tuesday, August 9th. Cantor Fitzgerald lowered their target price on Sarepta Therapeutics from $140.00 to $128.00 and set an “overweight” rating for the company in a research note on Friday, June 24th. Oppenheimer raised their price objective on Sarepta Therapeutics from $125.00 to $150.00 in a research note on Wednesday, August 3rd. Guggenheim raised their price objective on Sarepta Therapeutics from $100.00 to $122.00 in a research note on Wednesday, August 3rd. Finally, Barclays raised their price objective on Sarepta Therapeutics from $104.00 to $125.00 in a research note on Wednesday, August 3rd. Four equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $131.31.

Institutional Trading of Sarepta Therapeutics

Several hedge funds have recently made changes to their positions in SRPT. American Century Companies Inc. bought a new stake in shares of Sarepta Therapeutics in the 1st quarter worth approximately $63,986,000. Wellington Management Group LLP lifted its holdings in shares of Sarepta Therapeutics by 33.6% in the 1st quarter. Wellington Management Group LLP now owns 2,680,478 shares of the biotechnology company’s stock worth $209,399,000 after purchasing an additional 673,725 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of Sarepta Therapeutics by 14,938.5% in the 4th quarter. Marshall Wace LLP now owns 503,638 shares of the biotechnology company’s stock worth $45,352,000 after purchasing an additional 500,289 shares during the last quarter. Bank of Montreal Can raised its stake in Sarepta Therapeutics by 2,237.0% during the 1st quarter. Bank of Montreal Can now owns 481,366 shares of the biotechnology company’s stock valued at $37,832,000 after acquiring an additional 460,768 shares in the last quarter. Finally, Prudential Financial Inc. raised its stake in Sarepta Therapeutics by 1,473.5% during the 1st quarter. Prudential Financial Inc. now owns 396,074 shares of the biotechnology company’s stock valued at $30,942,000 after acquiring an additional 370,902 shares in the last quarter. Institutional investors own 82.18% of the company’s stock.

Sarepta Therapeutics Company Profile

(Get Rating)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.

See Also

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.